Secondhand smoke exposure and quality of life in patients with heart failure

Archives of Internal Medicine

Volumn 171, Issue 21, 2011, Pages 1887-1893

  Weeks, Sarah G ^a   Glantz, Stanton A ^b   De Marco, Teresa ^b   Rosen, Alisa B ^c   Fleischmann, Kirsten E ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; EMOTIONAL DISORDER; HEALTH PERCEPTIONS QUESTIONNAIRE; HEALTH SURVEY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SMOKE; UNIVARIATE ANALYSIS; URINE LEVEL;

EID: 82455206061     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.518     Document Type: Article

References (35)

1. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441-1446.
2. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-1435.
3. Agency for Healthcare Research and Quality. Hospitalization in the United States, 2002: executive summary. AHRQ Web site. http://www.ahrq.gov/data/hcup/ factbk6/factbk6a.htm. Accessed September 13, 2011.
4. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;37(6):1677-1682.
5. Glantz SA, Parmley WW. Even a little secondhand smoke is dangerous. JAMA. 2001;286(4):462-463. (Pubitemid 32681491)
6. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005;111(20):2684-2698. (Pubitemid 40740869)
7. Whincup PH, Gilg JA, Emberson JR, et al. Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ. 2004;329(7459):200-205.
8. Coghlin J, Hammond SK, Gann PH. Development of epidemiologic tools for measuring environmental tobacco smoke exposure. Am J Epidemiol. 1989;130(4):696-704. (Pubitemid 19240198)
9. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149-159.
10. Medical Outcomes Study: 36-Item Short Form Survey. http://www.rand.org/ health/surveys-tools/mos/mos-core-36item.html. Accessed September 6, 2011.
11. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30(6):473-483.
12. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919-923.
13. Mador MJ, Rodis A, Magalang UJ. Reproducibility of Borg scale measurements of dyspnea during exercise in patients with COPD. Chest. 1995;107(6):1590-1597.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
15. US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General - Executive Summary. Washington, DC: US Dept of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention, and Health Promotion, Office on Smoking and Health; 2006.
16. Heidenreich PA, Spertus JA, Jones PG, et al. Cardiovascular Outcomes Research Consortium. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol. 2006;47(4):752-756. (Pubitemid 43243096)
17. Fleischmann KE, Orav EJ, Lamas GA, et al. Pacemaker implantation and quality of life in the Mode Selection Trial (MOST). Heart Rhythm. 2006;3(6):653-659.
18. Taira DA, Seto TB, Ho KK, et al. Impact of smoking on health-related quality of life after percutaneous coronary revascularization. Circulation. 2000;102(12):1369-1374.
19. Eisner MD, Balmes J, Yelin EH, et al. Directly measured secondhand smoke exposure and COPD health outcomes. BMC Pulm Med. 2006;6:12. doi:10.1186/1471- 2466-6-12.
20. Halterman JS, Szilagyi PG, Yoos HL, et al. Benefits of a school-based asthma treatment program in the absence of secondhand smoke exposure: results of a randomized clinical trial. Arch Pediatr Adolesc Med. 2004;158(5):460-467. (Pubitemid 38623583)
21. Mody RR, Smith MJ. Smoking status and health-related quality of life: as findings from the 2001 Behavioral Risk Factor Surveillance System data. Am J Health Promot. 2006;20(4):251-258.
22. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36), II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247-263.
23. Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 1996;334(3):150-154. (Pubitemid 26017952)
24. Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 1990;81(3):772-779. (Pubitemid 20090372)
25. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol. 1992;19(5):918-925.
26. Robinson JD, Cinciripini PM. The effects of stress and smoking on catecholaminergic and cardiovascular response. Behav Med. 2006;32(1):13-18.
27. Høilund-Carlsen PF, Marving J, Gadsbøll N, et al. Acute effects of smoking on left ventricular function and neuro-humoral responses in patients with known or suspected ischaemic heart disease. Clin Physiol Funct Imaging. 2004;24(4):216-223. (Pubitemid 39077024)
28. Zhu BQ, Sievers RE, Browne AE, et al. The renin-angiotensin system does not contribute to the endothelial dysfunction and increased infarct size in rats exposed to second hand smoke. J Renin Angiotensin Aldosterone Syst. 2002;3(1):54-60. (Pubitemid 34467703)
29. Sinzinger H, Kefalides A. Passive smoking severely decreases platelet sensitivity to antiaggregatory prostaglandins. Lancet. 1982;2(8294):392-393. (Pubitemid 12093068)
30. Glantz SA, Parmley WW. Passive smoking and heart disease: epidemiology, physiology, and biochemistry. Circulation. 1991;83(1):1-12.
31. Sinzinger H, Virgolini I. Are passive smokers at greater risk of thrombosis [in German]? Wien Klin Wochenschr. 1989;101(20):694-698. (Pubitemid 19264662)
32. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al.; ATTICA study. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am J Med. 2004;116(3):145-150. (Pubitemid 38121670)
33. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47(2):332-337. (Pubitemid 43063250)
34. Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-1239.
35. Schane RE, Glantz SA. Education on the dangers of passive smoking: a cessation strategy past due. Circulation. 2008;118(15):1521-1523.